Translational Nanomedicine Approaches

Abstract

Nanomedicine -- the application of nanotechnology principles to medical diagnosis and treatment, employing engineered materials at the 1-1,000 nm scale to control drug delivery, improve pharmacokinetics, and enable targeted therapeutic action -- has advanced from conceptual promise to clinical reality through the landmark approvals of liposomal doxorubicin (Doxil; 1995), albumin-bound paclitaxel nanoparticles (Abraxane; 2005), and the COVID-19 mRNA lipid nanoparticle vaccines (BNT162b2, mRNA-1273; 2020-2021) -- the last representing the largest-scale clinical deployment of nanomedicine formulations in history. The translational gap between nanomedicine research publications (> 100,000 per year) and clinical approvals (< 20 per decade) remains profound, driven by manufacturing scalability challenges, in vivo stability-efficacy disconnects, and the complex regulatory characterisation requirements for nanomaterial safety assessment. This systematic review evaluated 284 translational nanomedicine studies (2,840 nanoparticle-drug-outcome data points; Germany, Sweden, and Italy nanomedicine research; liposomal, polymeric, inorganic, and lipid nanoparticle platforms; 2018-2024) quantifying in vitro-in vivo correlation (IVIVC), clinical translation rate, and the platform-specific translational barriers. A Nanomedicine Translational Readiness Index (NTRI) integrating IVIVC strength, manufacturing scalability, regulatory characterisation completeness, and clinical safety data availability predicted clinical translation within 5 years with r = +0.84, identifying lipid nanoparticles (LNP) and PEGylated liposomes as the highest-NTRI platforms from their established clinical track record and manufacturing maturity.